Merck & Co makes the accelerated approval pathway its own
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
New US nod widens the net for Entresto
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
Novartis’s canakinumab cancer test approaches
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
Zymeworks investors wake up to competition
With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
Go or no go? Oncology decisions ahead for the FDA
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
